Ident. | Authors (with country if any) | Title |
---|
000C64 (2012) |
Andrew Lees [Royaume-Uni] ; Stanley Fahn ; Karla M. Eggert ; Joseph Jankovic [États-Unis] ; Anthony Lang ; Federico Micheli ; M Maral Mouradian ; Wolfgang H. Oertel ; C Warren Olanow ; Werner Poewe [Autriche] ; Olivier Rascol ; Eduardo Tolosa ; David Squillacote ; Dinesh Kumar | Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. |
001030 (2012) |
Andrew Lees (neurologue) [Royaume-Uni] ; Stanley Fahn [États-Unis] ; Karla M. Eggert [Allemagne] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; Federico Micheli [Argentine] ; M. Maral Mouradian [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Eduardo Tolosa [Espagne] ; David Squillacote [États-Unis] ; Dinesh Kumar [États-Unis] | Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease |
001309 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
001385 (2011) |
Julia Grossac [France] ; Stéphanie Ruiz [France] ; Emmanuelle Bondon-Guitton [France] ; Franck-Emmanuel Roux [France] ; Olivier Fourcade [France] ; Jean-Louis Montastruc [France] ; Thomas Geeraerts [France] | Severe intracranial bleeding related to vitamin K Antagonist‐Ropinirole interaction |
001944 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
001B63 (2010) |
Sara Varanese [États-Unis, Italie] ; Jonathan Howard [États-Unis] ; Alessandro Di Rocco [États-Unis] | NMDA antagonist memantine improves levodopa‐induced dyskinesias and “On‐off” phenomena in Parkinson's disease |
002578 (2008) |
Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
002879 (2008) |
John G. Nutt [États-Unis] ; Steven A. Gunzler [États-Unis] ; Trish Kirchhoff [États-Unis] ; Penelope Hogarth [États-Unis] ; Jerry L. Weaver [États-Unis] ; Michael Krams [États-Unis] ; Brenda Jamerson [États-Unis] ; Frank S. Menniti [États-Unis] ; Jaren W. Landen [États-Unis] | Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism |
003245 (2006) |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
003845 (2005) |
Zhi Liu [Japon] ; Ryuji Sakakibara [Japon] ; Takeo Odaka [Japon] ; Tomoyuki Uchiyama [Japon] ; Tomoyuki Uchiyama [Japon] ; Tatsuya Yamamoto [Japon] ; Takashi Ito [Japon] ; Masato Asahina [Japon] ; Kazuya Yamaguchi [Japon] ; Taketo Yamaguchi [Japon] ; Takamichi Hattori [Japon] | Mosapride citrate, a novel 5‐HT4 agonist and partial 5‐HT3 antagonist, ameliorates constipation in parkinsonian patients |
003A19 (2005) |
Valerie E. Kelly [États-Unis] ; Amy J. Bastian [États-Unis] | Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements |
003A65 (2005) |
ZHI LIU [Japon] ; Ryuji Sakakibara [Japon] ; Takeo Odaka [Japon] ; Tomoyuki Uchiyama [Japon] ; Tomoyuki Uchiyama [Japon] ; Tatsuya Yamamoto [Japon] ; Takashi Ito [Japon] ; Masato Asahina [Japon] ; Kazuya Yamaguchi [Japon] ; Taketo Yamaguchi [Japon] ; Takamichi Hattori [Japon] | Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients |
004084 (2003) |
William G. Ondo [États-Unis] ; Christine Hunter [États-Unis] | Flumazenil, a GABA antagonist, may improve features of Parkinson's disease |
004085 (2003) |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] | Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease |
004745 (2001) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan |
004780 (2001) |
Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France] | Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease |
004905 (2000) |
H A Hana Asi [Turquie] ; G. Kaptanoglu ; H A Sahin ; M. Emre | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa. |
004937 (2000) |
Hasmet A. Hana Si [Turquie] ; Gülüstü Kaptano Lu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug‐resistant dyskinesias resulting from l‐dopa |
004B73 (2000) |
Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa |
004B93 (1999) |
B. Henry [Royaume-Uni] ; S H Fox ; D. Peggs ; A R Crossman ; J M Brotchie | The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. |
004C22 (1999) |
Brian Henry [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease |